Navigation Links
Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
Date:2/19/2008

000,000 shares authorized; 28,837,290 shares issued and

outstanding 288,372

Additional paid-in capital 100,969,362

Deficit accumulated during the development stage (60,199,556)

Total stockholders' equity 41,058,178

Total liabilities and stock and stockholders' equity $45,596,059

MEDIVATION, INC.

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENTS OF OPERATIONS

Inception

Year ended December 31, (September 4, 2003)

2007 2006 to December 31, 2007

Operating expenses:

General and administrative:

Payroll * $2,819,931 $937,677 $4,647,224

Consulting and other

professional fees * 4,086,689 1,964,819 7,952,822

Other general and

administrative 2,222,262 911,638 4,251,064

Total general and

administrative 9,128,882 3,814,134 16,851,110

Research and development:

Payroll * 5,321,212 1,358,735 7,693,780

Consulting and other

professional fees * 3,869,029 2,306,660 8,316,550

Preclinical and clinical

studies 14,088,491 8,405,044 26,658,806

Other research and

development 1,355,332 261,520 1,981,103

Total research and

development 24,634,064 12,331,959 44,650,239

Total operating expenses 33,762,946 16,146,093 61,501,349

Loss from operations (33,762,946
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
3. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
4. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
5. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
6. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
7. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
8. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
9. Escalon(R) Reports Second Quarter Fiscal 2008 Results
10. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
11. Eklin Medical Reports Record Revenues for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... to release financial results for the first quarter of ... market close in the US.  The ... ET on Friday, August 29, 2014 to discuss its ... Company,s recent developments, followed by a question and answer ...
(Date:8/21/2014)... 21, 2014 Pursuit Solutions ( ... technology and services for Life Sciences sales and ... Use of New Commercial Sales Models” by Peter ... , The article examines some innovative models used ... being tested in the pharmaceutical market. Robinson grades ...
(Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... full service biopharmaceutical contract development and manufacturing organization ... by Progenics Pharmaceuticals, Inc., an oncology company focused ... and treating cancer, to manufacture the anti-prostate specific ... PSMA ADC product candidate. Under the agreement ...
(Date:8/21/2014)... of last week RENU 28, the world's first and only ... purchase in Australia and New Zealand, and the response has ... if you think about the definition of aging, it's really ... your body. If you think about the definition of anti-aging, ... RENU 28 does is it works with these tiny little ...
Breaking Biology Technology:China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3RENU 28 Skin Care Now Available in Australia and New Zealand 2
... Kit produces cDNA , ideal for ... performed using real-time RT-PCR. The Cells-to-cDNA Kit comes in an , ... cells without RNA isolation in less than 2 ... Cell Lysis Buffer that inactivates RNases, RT-PCR can , ...
... , ... , Removes trace quantities of , ... RNase-free and recombinant in , ... lower in RNase activity than bovine pancreas , ...
... , ... , DNase enhancer increases the potency of TURBO DNase by ... , Remove DNase from RNA solutions in 5 minutes without phenol, alcohol, , ... TURBO DNase is RNase-free and recombinant in origin , The ...
Cached Biology Technology:Your Data: Detection of Oocyte-specific Gene Expression Using Ambion's Cells-to-cDNA Kit 2TURBO DNase: Hyperactive, Salt Tolerant DNase 2TURBO DNase: Hyperactive, Salt Tolerant DNase 3TURBO DNase: Hyperactive, Salt Tolerant DNase 4TURBO DNase: Hyperactive, Salt Tolerant DNase 5The World's Best DNase Improved TURBO DNA-free 2The World's Best DNase Improved TURBO DNA-free 3The World's Best DNase Improved TURBO DNA-free 4The World's Best DNase Improved TURBO DNA-free 5
(Date:8/21/2014)... a novel and versatile modeling strategy to simulate polyelectrolyte ... as well as for studying polyelectrolytes, including DNA and ... much larger and more complex polyelectrolyte systems, and to ... author of a paper on the work and a ... and Engineering. "This is a big step forward for ...
(Date:8/20/2014)... N.Y. In a study of 158 pregnant teenagers ... the craving and intentional consumption of ice, cornstarch, vacuum ... reports a new Cornell study. , Moreover, such teens ... who did not eat nonfood substances. , Pregnant teens, ... hemoglobin, which can lead to iron deficiency and anemia. ...
(Date:8/20/2014)... 20, 2014 /CNW/ -  Issue Serious ... quickly become life threatening for some children.    ... million Canadians have food allergies and this number may be ... children are estimated to have food allergies.  ... irritations and hives to breathing difficulties and loss of consciousness. ...
Breaking Biology News(10 mins):Researchers develop models to study polyelectrolytes, including DNA and RNA 2Pica in pregnant teens linked to low iron 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3
... Christian Koos has succeeded in developing a novel optical ... transmission rates in the range of several terabits per ... industrial scale. In the future, this technology may be ... and, thus, contribute to reducing energy consumption of the ...
... the first researchers to study the deadly link between ... Association lifetime achievement award today at a ceremony in ... endocrinologist James Sowers, MD, recognizes his more than 30 ... The Irvine Page-Alva Bradley Lifetime Achievement Award in ...
... question about it they,re very good at what they do. ... to carry out inspection work in oily or dangerous environments, ... Still, they,re one of the fastest and most maneuverable ... and low speeds due to their streamlined bodies and a ...
Cached Biology News:Optical waveguide connects semiconductor chips 2Pioneering researcher receives Heart Association Lifetime Achievement Award 2Pioneering researcher receives Heart Association Lifetime Achievement Award 3Robotic tuna is built by Homeland Security 2